The United Laboratories International (HKG:3933) said the Roxithromycin Capsules passed China's National Medical Products Administration's consistency evaluation of quality and efficacy for generic drugs, according to a Monday Hong Kong bourse filing.
The drug was submitted by unit Zhuhai United Laboratories' Zhongshan Branch.
Roxithromycin Capsules are indicated to treat infections of the ear, nose and throat, respiratory tract, skin and soft tissues, and the genitourinary tract caused by pathogens susceptible to roxithromycin.